Connect with us
  • ciitech

Industry

Taking a natural approach to CBD

Published

on

Share Natur uses unique harvesting methods to deliver its 100% natural range of CBD products

Alexander Berg once held the record for the most push-ups per minute, with an impressive 101. He achieved the feat just a few years after a life changing injury left him with chronic back pain. The 35-year-old attributes this achievement to his lifestyle choices and CBD regime.

Berg works as the Business Development executive and subject matter-expert at a CBD products company, Share Natur, and is a passionate advocate for the benefits of the cannabis plant. He had his injury seven years ago at just 28 years old, leaving him debilitated due to the pain.

He tried a number of prescribed medications, but the negative side effects became too much to bear. As pill after pill failed to control his pain, Berg took matters into his own hands, changing his lifestyle in an effort to rebuild his life.

He now lives on a completely plant-based diet and has adapted the way he moves and breathes in order to control the pain.

However, above all else, it is cannabis that has made the biggest impact on his life. He says: “Cannabis is a massive part of my life now. Since my injury, I have experienced a lot of pain and I have been on many different pills that just didn’t work for me; I lost 30kg of weight in eight months when I started on morphine.

“The cannabis plant changed my life because it opened up doors. It made me feel again and it made me passionate.

“I’ve experienced a lot of bad things in my life, but I’ve been able to change that by doing things the right way. I’ve been able to reduce my pain by moving and breathing correctly, eating fruits, getting the right amount of sun and taking CBD and THC. I’ve lowered my pain so much that I can thrive; I’ve never been stronger in my life.”

Share Natur is a Dutch company headquartered in Amsterdam known for using CBD to elevate products in multiple categories, from droppers, capsules and creams to infusing CBD in food and beverages such as water and gummies.

Its products are 100% natural thanks to a number of unconventional processes that aim to bring the company as close to nature as possible. Rather than using traditional methods for extracting CBD from hemp, such as carbon dioxide or alcohol extraction, Share Natur is one of the only companies in Europe to use cold pressed technology.

Compared to conventional hemp oils, cold-pressed products contain a higher volume of the nutrients, natural fats, vitamins and phytocannabinoids from the original hemp plant.

Berg explains: “With CO2 and alcohol extraction methods, companies are using lots of different solvents and emulsifiers. Our cold-pressed solution simply squeezes cannabinoids meaning they remain more in-tact but still gets rid of the acid bindings of the CBD.”

The company says this technique improves bioavailability, which means more CBD is absorbed into the body. A normal CBD oil has an absorption of 3 to 5% of active CBD in your bloodstream within 190 min, but with Share Natur’s range of carriers, which are also cold-pressed, the absorption can be increased dramatically.

Their new bioavailability studies is released start next year. “You are not what you eat,” Berg says. “You are what you absorb, so bioavailability is very important. If you don’t have a very healthy lifestyle or if you are stressed, this tool can help you get in balance quicker than normal.”

In addition to its CBD oil, Share Natur has also developed something called HempCap, a CBD powder derived from hemp. The powder is micro-encapsulated meaning it can be fully dissolved into water without affecting the taste.

Encapsulation involves surrounding small particles with a coating. In the case of HempCap, this coating is from proteins. When the product reaches the stomach, the only thing the body needs to do is break down these proteins to fully release the compounds within the hemp.

According to Share Natur, the result of this process is an effect that is fifty-two times greater than that produced by nonencapsulated CBD products.

Berg says: “The amazing thing about bringing the CBD to your stomach is that CBD will be broken down differently than in your liver. Some of the CBD will convert over to something called THC Delta 8.

“THC Delta 8 is not very psychoactive, as THC Delta 9 is, but it has all the other properties and benefits of Delta 9.

“You can convert the CBD into THC Delta 8 and something called 11-Hydroxy-THC which is very suitable for sick people, specifically those with cancer, because it reaches the cells and penetrates them quicker and brings all the other cannabinoids with it.”

Share Natur is looking for new ways to further enhance the effectiveness of CBD. Playing a key role in this push is the ‘entourage effect’, which was discovered in 1998 by the Israeli cannabis expert, Dr. Raphael Mechoulam.

This theory claims that the many and varied compounds found in the cannabis plant, including CBD, THC, terpenes and flavonoids, work together to produce therapeutic effects. In other words, the combination of cannabinoids has more benefits when consumed together than separately, commonly known as an isolate.

Share Natur has created a range of products called Full Spectrum, which combines the various compounds found within industrial hemp. This includes a tiny amount of THC, which Berg says helps reduce the time it takes for the cannabinoids to reach the cells.

“We are developing new products where the CBD can be read by the body quicker,” Berg says. “We have found that if we don’t change the cannabinoids and if we have the complete solution of the terpenes as well as CBD and other compounds, they will help each other.

“It’s like a symphony orchestra where the CBD is the conductor and the rest of the terpenoids, cannabinoids, flavonoids, terpenes, minerals and fatty acids, are the different instruments. Hence we call these products Full Spectrum, but with our unique processing techniques we also develop Broad Spectrum products fully omitting THC ”

Find out more about Share Natur at sharenatur.com or follow them on Instagram @sharenatur

Industry

Cannabliss to open brick and mortar dispensary

Published

on

Michael Dobson - Cannabliss founder

UK-based medical cannabis group, Cannabliss aims to help patients transition from the illicit market into the legal cannabis space.

Following a long, “drawn-out” application process, Cannabliss has secured a pharmacy licence for dispensing medical cannabis through its online platform.

Now, after handing out its first private prescription this month, the company has announced it will be opening a brick and mortar site in Preston in April 2021.

Set to open on 12 April, the store will sell legal, over-the-counter cannabis-based products and also offer advice and guidance to people who are seeking to secure a medical cannabis prescription.

Cannabliss was founded by Michael Dobson, who was involved in a legal battle for several years over the legality of cultivating cannabis plants. In a saga that climaxed with him taking the then Home Secretary, Amber Rudd to court, he fought for a judicial review of cannabis legislation.

Having spent many years involved with the illicit cannabis market, including a period behind bars for growing several of his own plants, Dobson is now on a mission to widen access to legal medical cannabis.

“The vast majority of people have very little understanding of the legal cannabis market,” he tells Cannabis Health.

“What we’re doing is effectively creating a concierge service in which we help guide [people] through the process of becoming a legalised cannabis patient.”

Cannabliss says it aims to build trust with its customers and establish itself as a “go-to” place for trusted information about the medical cannabis landscape.

Dobson explains: “Customers have the opportunity to have a face-to-face conversation with somebody who specialises in this particular area, rather than it just being a vape shop or health food store that has added cannabis products to its already existing range.

“If we do have somebody coming in and asking about the process of getting access to medical cannabis, we can explain that to them.”

Currently, in the UK, there are qualifying conditions that must be met before being considered for cannabis-based treatment.

Although an estimated 1.4 million people consume cannabis for medicinal purposes, very few can access it via a prescription.

Dobson believes that there is a “great deal” of people that could meet the criteria for a medical cannabis prescription but have never considered it due to the cost and exclusivity of private healthcare.

He says Cannabliss will provide support to its customers if they choose to go through the official process.

“Even though the prices have dropped significantly over the past few years, we still think there’s going to be a hurdle to overcome in terms of breaking down that barrier; that stigma that is there for a lot of people,” he says.

The company is already putting plans in motion to expand into a franchise with two provisional stores set to open this summer in Leicester and Essex.

As part of this franchising effort, Cannabliss aims to provide opportunities for people who may have previously been involved with the illicit cannabis market.

Dobson believes that it is “morally right” to give people the chance to enter the burgeoning legal market.

“I always wanted to include as many people as possible within what we’re doing, and support people that have been in a similar position to myself,” Dobson adds.

“We will not discriminate on somebody because they maybe have a criminal history like myself.

“In actual fact, these people are actually the best people to have running our franchises because they’re so knowledgeable.”

Dobson also believes that this approach could help reduce the influence and scale of the illegal market.

“By removing people from the illegal market and bringing them into the legal market, you’re getting rid of the black market rather than putting something in place that’s in competition with it,” he says.

Looking ahead, Dobson says the company is feeling “very positive”. It has formed partnerships with suppliers in the UK and Europe, including a distribution agreement with Canopy Growth Corporation subsidiary, Storz and Bickel, for its range of medical-grade vaporisers.

“It’s going very well and we’re anticipating a lot of interest,” Dobson adds.

“Feedback that I’m getting from different people [in the sector] is that a lot of people are interested in what we’re doing, how we’ve got to where we’ve got to and, in particular, my backstory and how that fed into the whole ethos of what we’re trying to do.

“I feel very strongly that the UK is going to become a world leader in the legalised cannabis space over the next few years and I’m looking forward to playing my own small part in that.”

Continue Reading

Industry

Twitter’s Katie Ford joins Fyllo to focus on cannabis sector

Published

on

Katie Ford - former head of global brands for Twitter

Tech and media leaders are shunning social media giants to bring their expertise to the cannabis industry.

Twitter’s former head of global brands, Katie Ford has announced she is joining cannabis marketing company Fyllo as chief operating officer.

Fyllo is working with major cannabis companies to enable them to advertise to mainstream consumers.

Ford was previously at Twitter where she served for the past two years as head of global brands and is one of the biggest names in digital media, with a career built at Fortune 100 media & technology companies at the intersection of data, marketing, and creativity. 

She spent two plus decades at Publicis Media, rising to the rank of president where she was the Executive lead on P&G, Coca-Cola, USAA, and Kellogg’s accounts.

During her time at Publicis she was recognized by Ad Age as one of the “Women to Watch,” and by Campaign US, as a leading “Media Maven.” 

From there she joined Amobee’s executive team as chief client officer, where she was integral in delivering two successful acquisitions within 18 months, along with achieving positive EBITDA with over $1billion in annual revenue. 

The Fyllo Compliance Cloud is a suite of software and services built to overcome the complexities of highly regulated industries.

With 2021 shaping up to be a transformational year for cannabis, Fyllo now allows cannabis brands to market themselves at a scale that has never been possible for companies that operate in highly regulated industries.

Mainstream brands also seek out Fyllo’s Data Marketplace to target previously inaccessible cannabis and CBD consumers.

Ford was the first person to be appointed to Fyllo’s board of directors, a role she’s held since 2019.

“Katie has been an incredible partner since day one, always believing in the company and its mission,” said Chad Bronstein, founder and CEO of Fyllo.

“She was the first person to join our Board and has been instrumental in Fyllo’s creation, growth and development.”

Ford added: “Fyllo has built incredible products and proven their business model in a very short period of time.

“I look forward to being part of Fyllo’s success as we build breakthrough solutions for companies in highly regulated industries like cannabis, pharma, and alcohol.”

As COO, Ford will depart Fyllo’s board of directors to assume her new executive position.

Continue Reading

Industry

Kanabo brings its unique VapePod to UK patients

Published

on

The VapePod can administer a measured dose of cannabis extract

Following its listing on the London Stock Exchange (LSE) cannabis company Kanabo is set to make its unique vaporiser available to UK patients. 

A week after it became the second company to list on the LSE, Israeli firm Kanabo, has announced it will supply its medical-grade inhalation device, VapePod and a line of medicinal cannabis formulations in pods for the UK market. 

The company has signed its first distribution agreement with the UK’s biggest cannabis clinic provider, LYPHE Group, which is part of Drug Science’s Project Twenty21. 

Through this new agreement, Kanabo’s VapePod medicinal cannabis formula, will be made available to Project Twenty21 patients under LYPHE Group’s brand NOIDECS.

Kanabo seeks to provide an alternative solution to the smoking of medicinal cannabis flowers.

The VapePod will be the first product of its kind, a medical-grade handheld vaporiser with controlled metered dosage, made available to UK cannabis patients with a medical prescription. 

It can administer an accurate, measured dose of cannabis extract, which the company hopes will improve patient access and boost trust amongst medical professionals.

The initial formula, which Astral Health will distribute under the name NOIDECS 400T, is based on the Israeli medical cannabis pharmacopoeia as a recommended ratio for pain management. 

Kanabo and Astral Health will work closely to make the products available to patients over the coming months.

Avihu Tamir, Kanabo’s CEO commented: “We believe this new product will be revolutionary for medical cannabis patients who need immediate relief of pain, and will replace the smoking of cannabis flowers as a medical delivery method, which is one of Kanabo’s main targets.”

Kanabo founder, Avihu Tamir

Project Twenty21 provides eligible patients with affordable medical cannabis treatment, monitored by Drug Science and aims to create the UK’s largest body of evidence for the effectiveness and tolerability of medical cannabis.

LYPHE Group announced its partnership with Project Twenty21 in December to bring a range of EU-GMP and equivalent GMP medicines to the UK.

LYPHE Group, which has more than 60 percent of the British patient market, recently entered into a supply partnership with Canadian manufacturer, Northern Green to bring a range of indoor grown flower-based products to the market.

Dean Friday, LYPHE’s CEO added: “We have seen the headlines, and we have witnessed the negative impact of opioids. Pain is not going to go away, so a more natural and caring approach to treating it must find centre stage. Thanks to our partnership with Kanabo we now have a metered dose NOIDECS product that can treat patients across the U.K. that suffer from chronic pain.”

Continue Reading

Trending